HDAC2 and neoplasm: While several reports suggest a number of HDAC inhibitor targets, both histone and non-histone, as relevant for their observed anti-tumour activity, our preclinical data suggest that the depletion of HDAC2 by siRNA is sufficient, as its depletion mimics the effects of an HDAC inhibitor–tamoxifen combination in vitro.